GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » YoY EPS Growth

CureVac NV (WBO:CVAC) YoY EPS Growth : 61.54% (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is CureVac NV YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. CureVac NV's YoY EPS Growth for the quarter that ended in Dec. 2024 was 61.54%.

CureVac NV's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was €-0.15.

CureVac NV YoY EPS Growth Historical Data

The historical data trend for CureVac NV's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV YoY EPS Growth Chart

CureVac NV Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EPS Growth
Get a 7-Day Free Trial -72.54 -125.51 40.27 10.61 161.02

CureVac NV Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.65 -14.81 -6.67 781.82 61.54

CureVac NV YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

CureVac NV's YoY EPS Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EPS Growth (A: Dec. 2024 )
=(Earnings per Share (Diluted) (A: Dec. 2024 )-Earnings per Share (Diluted) (A: Dec. 2023 ))/ | Earnings per Share (Diluted) (A: Dec. 2023 ) |
=(0.72--1.18)/ | -1.18 |
=161.02 %

CureVac NV's YoY EPS Growth for the quarter that ended in Dec. 2024 is calculated as:

YoY EPS Growth (Q: Dec. 2024 )
=(Earnings per Share (Diluted) (Q: Dec. 2024 )-Earnings per Share (Diluted) (Q: Dec. 2023 )) / | Earnings per Share (Diluted) (Q: Dec. 2023 )) |
=(-0.15--0.39)/ | -0.39 |
=61.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CureVac NV YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of CureVac NV's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » YoY EPS Growth
Comparable Companies
PRAX IMNM NUVB LENZ AVBP XNCR REPL DNTH ABCL QURE VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
CVAC:USA 1CVAC:Italy 0A9E:UK 5CV:Germany 5CV:Germany 5CV:Germany 5CV:Germany
Address
Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076
Website
https://www.curevac.com
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.